Viewing data from:

TEMOZOLOMIDE

ANDA

TEMOZOLOMIDE | A078879 | HERITAGE PHARMA LABS INC DBA AVET PHARMA LABS INC

6 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Temozolomide (2023)

Total Spending

$89K

Total Claims

141

Beneficiaries

Avg Cost/Unit

$74.18

Spending Trend

$203K(2020)→$257K(2021)→$117K(2022)→$89K(2023)

YoY Change:+34.2%

5yr CAGR:+9.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain13 active DMFs1 inactive

13 active API suppliers hold Drug Master Files for this ingredient.

WAVELENGTH ENTERPRISES LTDTEMOZOLOMIDE

DMF 193472006

JIANGSU TASLY DIYI PHARMACEUTICAL CO LTDTEMOZOLOMIDE (BULK, NON-STERILE ACTIVE PHARMACEUTICAL INGREDIENT)

DMF 216692008

RELIANCE LIFE SCIENCES PVT LTDTEMOZOLOMIDE USP

DMF 227752009

FORMOSA LABORATORIES INCTEMOZOLOMIDE

DMF 231582009

SHILPA PHARMA LIFESCIENCES LTDTEMOZOLOMIDE USP

DMF 234792010

CHEMWERTH INCTEMOZOLOMIDE (NON-STERILE BULK DRUG SUBSTANCE)

DMF 235472010

SUN PHARMACEUTICAL INDUSTRIES LTDTEMOZOLOMIDE USP

DMF 235532010

GLOPEC INTERNATIONAL INCTEMOZOLOMIDE

DMF 241732010

SYNTHIMED LABS PRIVATE LTDTEMOZOLOMIDE USP

DMF 242982010

BEIJING LUNARSUN PHARMACEUTICAL CO LTDTEMOZOLOMIDE

DMF 243522010

EXCELLA GMBH AND CO KGTEMOZOLOMIDE

DMF 260322012

HUBEI HAOSUN PHARMACEUTICAL CO LTDTEMOZOLOMIDE

DMF 277152013

AMPAC FINE CHEMICALS LLCTEMOZOLOMIDE

DMF 285802014

CIPLA LTDInactiveTEMOZOLOMIDE USP

DMF 290282015

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.